The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
Identifieur interne : 001350 ( Main/Exploration ); précédent : 001349; suivant : 001351The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease
Auteurs : Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-10.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Autonomic Nervous System Diseases (drug therapy), Autonomic Nervous System Diseases (etiology), Cognition Disorders (drug therapy), Cognition Disorders (etiology), Dopamine agonist, Evidence-Based Medicine, Evidence-based medicine, Humans, Mental Disorders (drug therapy), Mental Disorders (etiology), Mood Disorders (drug therapy), Mood Disorders (etiology), Motor system disorder, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson Disease (therapy), Parkinson disease, Parkinson's disease, Psychotropic Drugs (therapeutic use), Randomized Controlled Trials as Topic, Reuptake inhibitor, Serotonin, Sleep Disorders, Intrinsic (drug therapy), Sleep Disorders, Intrinsic (etiology), Transcranial magnetic stimulation, Treatment, Treatment Outcome, dopamine agonists, evidence‐based medicine, omega‐3 fatty‐acids, selective serotonin reuptake inhibitors (SSRIs), transcranial magnetic stimulation, tricyclic antidepressants.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Psychotropic Drugs.
- drug therapy : Autonomic Nervous System Diseases, Cognition Disorders, Mental Disorders, Mood Disorders, Parkinson Disease, Sleep Disorders, Intrinsic.
- etiology : Autonomic Nervous System Diseases, Cognition Disorders, Mental Disorders, Mood Disorders, Sleep Disorders, Intrinsic.
- psychology : Parkinson Disease.
- therapy : Parkinson Disease.
- Evidence-Based Medicine, Humans, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
The Movement Disorder Society (MDS) Task Force on Evidence‐Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non‐motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms. Level‐I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non‐motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non‐efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty‐four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non‐motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX‐A) and BTX‐B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non‐motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω‐3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above‐mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short‐term management of the different non‐motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication‐related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non‐motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society
Url:
- https://api.istex.fr/document/212571482820B6BC4BA0BB8AFF1B9B453FAD53EE/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020145
DOI: 10.1002/mds.23884
Affiliations:
- Autriche, Canada, France, Portugal, États-Unis
- Illinois, Midi-Pyrénées, Pennsylvanie, Tyrol (Land), Vienne (Autriche)
- Innsbruck, Toulouse, Vienne (Autriche)
- Université Toulouse III - Paul Sabatier, Université de Toulouse, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000128
- to stream Istex, to step Curation: 000128
- to stream Istex, to step Checkpoint: 000082
- to stream Pmc, to step Corpus: 000252
- to stream Pmc, to step Curation: 000252
- to stream Pmc, to step Checkpoint: 000227
- to stream PubMed, to step Corpus: 000F73
- to stream PubMed, to step Curation: 000F73
- to stream PubMed, to step Checkpoint: 001063
- to stream Ncbi, to step Merge: 003443
- to stream Ncbi, to step Curation: 003443
- to stream Ncbi, to step Checkpoint: 003443
- to stream Main, to step Merge: 001403
- to stream PascalFrancis, to step Corpus: 000358
- to stream PascalFrancis, to step Curation: 002956
- to stream PascalFrancis, to step Checkpoint: 000361
- to stream Main, to step Merge: 001951
- to stream Main, to step Curation: 001350
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease</title>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
</author>
<author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
</author>
<author><name sortKey="Hametner, Eva Aria" sort="Hametner, Eva Aria" uniqKey="Hametner E" first="Eva-Maria" last="Hametner">Eva-Maria Hametner</name>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><country>Autriche</country>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:212571482820B6BC4BA0BB8AFF1B9B453FAD53EE</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23884</idno>
<idno type="url">https://api.istex.fr/document/212571482820B6BC4BA0BB8AFF1B9B453FAD53EE/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000128</idno>
<idno type="wicri:Area/Istex/Curation">000128</idno>
<idno type="wicri:Area/Istex/Checkpoint">000082</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Seppi K:the:movement:disorder</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020145</idno>
<idno type="RBID">PMC:4020145</idno>
<idno type="wicri:Area/Pmc/Corpus">000252</idno>
<idno type="wicri:Area/Pmc/Curation">000252</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000227</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000F73</idno>
<idno type="wicri:Area/PubMed/Curation">000F73</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001063</idno>
<idno type="wicri:Area/Ncbi/Merge">003443</idno>
<idno type="wicri:Area/Ncbi/Curation">003443</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003443</idno>
<idno type="wicri:Area/Main/Merge">001403</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:12-0019604</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000358</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002956</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000361</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Seppi K:the:movement:disorder</idno>
<idno type="wicri:Area/Main/Merge">001951</idno>
<idno type="wicri:Area/Main/Curation">001350</idno>
<idno type="wicri:Area/Main/Exploration">001350</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease</title>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Klaus Seppi, Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A‐6020 Innsbruck, AustriaCristina Sampaio, Instituto de Medicina Molecular, University of Lisbon, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, University of Pennsylvania School of Medicine; Parkinson's Disease and Mental Illness Research, Education and Clinical Centers (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Neurological Clinical Research Unit, Instituto de Medicina Molecular, Hospital Santa Maria, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorder Clinic, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation wicri:level="3"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Danube Hospital/SMZ‐Ost, Vienna</wicri:regionArea>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hametner, Eva Aria" sort="Hametner, Eva Aria" uniqKey="Hametner E" first="Eva-Maria" last="Hametner">Eva-Maria Hametner</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Medical University Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
<placeName><settlement type="city">Innsbruck</settlement>
<region nuts="2" type="region">Tyrol (Land)</region>
</placeName>
<orgName type="university">Université de médecine d'Innsbruck</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Instituto de Medicina Molecular, University of Lisbon, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Portugal</country>
<wicri:regionArea>Klaus Seppi, Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A‐6020 Innsbruck, AustriaCristina Sampaio, Instituto de Medicina Molecular, University of Lisbon, Lisbon</wicri:regionArea>
<wicri:noRegion>Lisbon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-10">2011-10</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">S3</biblScope>
<biblScope unit="supplement">S3</biblScope>
<biblScope unit="page" from="S42">S42</biblScope>
<biblScope unit="page" to="S80">S80</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">212571482820B6BC4BA0BB8AFF1B9B453FAD53EE</idno>
<idno type="DOI">10.1002/mds.23884</idno>
<idno type="ArticleID">MDS23884</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Autonomic Nervous System Diseases (drug therapy)</term>
<term>Autonomic Nervous System Diseases (etiology)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Dopamine agonist</term>
<term>Evidence-Based Medicine</term>
<term>Evidence-based medicine</term>
<term>Humans</term>
<term>Mental Disorders (drug therapy)</term>
<term>Mental Disorders (etiology)</term>
<term>Mood Disorders (drug therapy)</term>
<term>Mood Disorders (etiology)</term>
<term>Motor system disorder</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Psychotropic Drugs (therapeutic use)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Reuptake inhibitor</term>
<term>Serotonin</term>
<term>Sleep Disorders, Intrinsic (drug therapy)</term>
<term>Sleep Disorders, Intrinsic (etiology)</term>
<term>Transcranial magnetic stimulation</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>dopamine agonists</term>
<term>evidence‐based medicine</term>
<term>omega‐3 fatty‐acids</term>
<term>selective serotonin reuptake inhibitors (SSRIs)</term>
<term>transcranial magnetic stimulation</term>
<term>tricyclic antidepressants</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Psychotropic Drugs</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
<term>Cognition Disorders</term>
<term>Mental Disorders</term>
<term>Mood Disorders</term>
<term>Parkinson Disease</term>
<term>Sleep Disorders, Intrinsic</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term>
<term>Cognition Disorders</term>
<term>Mental Disorders</term>
<term>Mood Disorders</term>
<term>Sleep Disorders, Intrinsic</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Evidence-Based Medicine</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Inhibiteur recapture</term>
<term>Maladie de Parkinson</term>
<term>Médecine factuelle</term>
<term>Pathologie du système nerveux</term>
<term>Stimulant dopaminergique</term>
<term>Stimulation magnétique transcrânienne</term>
<term>Sérotonine</term>
<term>Traitement</term>
<term>Trouble moteur</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The Movement Disorder Society (MDS) Task Force on Evidence‐Based Medicine (EBM) Review of Treatments for Parkinson's Disease (PD) was first published in 2002 and was updated in 2005 to cover clinical trial data up to January 2004 with the focus on motor symptoms of PD. In this revised version the MDS task force decided it was necessary to extend the review to non‐motor symptoms. The objective of this work was to update previous EBM reviews on treatments for PD with a focus on non‐motor symptoms. Level‐I (randomized controlled trial, RCT) reports of pharmacological and nonpharmacological interventions for the non‐motor symptoms of PD, published as full articles in English between January 2002 and December 2010 were reviewed. Criteria for inclusion and ranking followed the original program outline and adhered to EBM methodology. For efficacy conclusions, treatments were designated: efficacious, likely efficacious, unlikely efficacious, non‐efficacious, or insufficient evidence. Safety data were catalogued and reviewed. Based on the combined efficacy and safety assessment, Implications for clinical practice were determined using the following designations: clinically useful, possibly useful, investigational, unlikely useful, and not useful. Fifty‐four new studies qualified for efficacy review while several other studies covered safety issues. Updated and new efficacy conclusions were made for all indications. The treatments that are efficacious for the management of the different non‐motor symptoms are as follows: pramipexole for the treatment of depressive symptoms, clozapine for the treatment of psychosis, rivastigmine for the treatment of dementia, and botulinum toxin A (BTX‐A) and BTX‐B as well as glycopyrrolate for the treatment of sialorrhea. The practical implications for these treatments, except for glycopyrrolate, are that they are clinically useful. Since there is insufficient evidence of glycopyrrolate for the treatment of sialorrhea exceeding 1 week, the practice implication is that it is possibly useful. The treatments that are likely efficacious for the management of the different non‐motor symptoms are as follows: the tricyclic antidepressants nortriptyline and desipramine for the treatment of depression or depressive symptoms and macrogol for the treatment of constipation. The practice implications for these treatments are possibly useful. For most of the other interventions there is insufficient evidence to make adequate conclusions on their efficacy. This includes the tricyclic antidepressant amitriptyline, all selective serotonin reuptake inhibitors (SSRIs) reviewed (paroxetine, citalopram, sertraline, and fluoxetine), the newer antidepressants atomoxetine and nefazodone, pergolide, Ω‐3 fatty acids as well as repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression or depressive symptoms; methylphenidate and modafinil for the treatment of fatigue; amantadine for the treatment of pathological gambling; donepezil, galantamine, and memantine for the treatment of dementia; quetiapine for the treatment of psychosis; fludrocortisone and domperidone for the treatment of orthostatic hypotension; sildenafil for the treatment of erectile dysfunction, ipratropium bromide spray for the treatment of sialorrhea; levodopa/carbidopa controlled release (CR), pergolide, eszopiclone, melatonin 3 to 5 mg and melatonin 50 mg for the treatment of insomnia and modafinil for the treatment of excessive daytime sleepiness. Due to safety issues the practice implication is that pergolide and nefazodone are not useful for the above‐mentioned indications. Due to safety issues, olanzapine remains not useful for the treatment of psychosis. As none of the studies exceeded a duration of 6 months, the recommendations given are for the short‐term management of the different non‐motor symptoms. There were no RCTs that met inclusion criteria for the treatment of anxiety disorders, apathy, medication‐related impulse control disorders and related behaviors other than pathological gambling, rapid eye movement (REM) sleep behavior disorder (RBD), sweating, or urinary dysfunction. Therefore, there is insufficient evidence for the treatment of these indications. This EBM review of interventions for the non‐motor symptoms of PD updates the field, but, because several RCTs are ongoing, a continual updating process is needed. Several interventions and indications still lack good quality evidence, and these gaps offer an opportunity for ongoing research. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Canada</li>
<li>France</li>
<li>Portugal</li>
<li>États-Unis</li>
</country>
<region><li>Illinois</li>
<li>Midi-Pyrénées</li>
<li>Pennsylvanie</li>
<li>Tyrol (Land)</li>
<li>Vienne (Autriche)</li>
</region>
<settlement><li>Innsbruck</li>
<li>Toulouse</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
<li>Université de médecine d'Innsbruck</li>
</orgName>
</list>
<tree><country name="Autriche"><noRegion><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</noRegion>
<name sortKey="Hametner, Eva Aria" sort="Hametner, Eva Aria" uniqKey="Hametner E" first="Eva-Maria" last="Hametner">Eva-Maria Hametner</name>
<name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
</country>
<country name="Portugal"><noRegion><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
</noRegion>
<name sortKey="Coelho, Miguel" sort="Coelho, Miguel" uniqKey="Coelho M" first="Miguel" last="Coelho">Miguel Coelho</name>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
</country>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Weintraub, Daniel" sort="Weintraub, Daniel" uniqKey="Weintraub D" first="Daniel" last="Weintraub">Daniel Weintraub</name>
</region>
<name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</country>
<country name="France"><noRegion><name sortKey="Perez Loret, Santiago" sort="Perez Loret, Santiago" uniqKey="Perez Loret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name>
</noRegion>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</country>
<country name="Canada"><noRegion><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001350 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001350 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:212571482820B6BC4BA0BB8AFF1B9B453FAD53EE |texte= The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |